Loading clinical trials...
Loading clinical trials...
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approxima...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Corcept Therapeutics
NCT07412782 · Osteogenesis Imperfecta, Osteoporosis, and more
NCT04388124 · Resistant Hypertension
NCT06246357 · Hyperaldosteronism, Hypercortisolism, and more
NCT06526858 · Resistant Hypertension
NCT07081243 · Resistant Hypertension
Site 378
Huntington Park, California
Site 406
La Jolla, California
Site 538
La Jolla, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions